Experimental cancer combo trial halted early
NCT ID NCT04234113
First seen Apr 05, 2026 · Last updated Apr 28, 2026 · Updated 6 times
Summary
This early-phase study tested a new drug called SO-C101, either by itself or combined with the immunotherapy pembrolizumab, in 115 people with various advanced solid tumors (like lung, kidney, or skin cancer) that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was terminated early, so final results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, France, 69379, France
-
Hopital Saint Louis
Paris, 75010, France
-
Hôpitaux Universitaires de Marseille Timone
Marseille, 13005, France
-
Institut Claudius Regaud
Toulouse, France, 31059, France
-
Institut Gustave Roussy
Paris, France, 94805, France
-
Institut de Cancerologie de L'Ouest
Saint-Herblain, 44805, France
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Masarykův Onkologický Ústav Brno Klinika komplexní onkologické péče
Brno, Czechia, 65653, Czechia
-
University Hospital Sanchinarro
Madrid, 28050, Spain
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15216, United States
-
Vall d'Hebron Institute of Oncology
Barcelona, Spain, 08035, Spain
-
Yale Cancer Center
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.